Abstract 116P
Background
Colorectal cancer (CRC) ranks as the second leading cause of mortality, following lung cancer, among cancer-related fatalities in High Income Asia Pacific (HIAP) nations. Despite this, there remains a lack of consistent and comparable data on the burden of CRC in these regions.
Methods
Utilizing tools from the Global Burden of Disease study, we examined CRC's prevalence, incidence, mortality, and disability-adjusted life years (DALYs) by age groups, sex, and years across four HIAP countries from 1990-2019. Moreover, we employed a regression framework model to project CRC-related deaths until 2040.
Results
The aggregate number of prevalent CRC cases surged from 450,169 (95%UI: 433,127-466,354) in 1990 to 1,178,847 (1,026,274-1,347,590) in 2019. During the same period, the death toll increased from 34,338 (32,598-35,179) to 76,929 (64,820-83,603). When considering the annual percentage change (APC), DALYs exhibited a 65% increase from 1990 to 2019. Notably, the age-standardized incidence rate (ASIR) demonstrated a 15% rise in APC, with the most pronounced increases occurring in South Korea (119%), Brunei Darussalam (21%), and Japan (13%). Conversely, Singapore exhibited a 7% decline in ASIR during the same timeframe. In terms of age-standardized mortality rate (ASMR), South Korea reported the highest APC (17%), while Singapore and Japan witnessed declines of 40% and 15%, respectively. The most significant APC in DALYs was noted in Brunei Darussalam (178%), trailed by South Korea (176%), Japan (89%), and Singapore (50%). In 2019, the age group of 85-89 experienced the highest CRC-related deaths, whereas the 75-79 age group exhibited the highest incidence. Meanwhile, the 70-74 age group showed the highest DALYs. Over the past three decades, males carried a greater burden compared to females. By 2040, a projected increase of 73,633 (52,895-102,526) CRC-related deaths is anticipated.
Conclusions
In 2019, CRC contributed to 13.88% of all cancer-related casualties in HIAP nations. The burden of CRC varied persistently among these countries. Nonetheless, it is evident that there is an urgent requirement for the implementation of more effective strategies to mitigate the burden posed by CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract